HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Roivant Sciences (NASDAQ:ROIV) with a maintained price target of $18.
April 22, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences receives a reiterated Buy rating and an $18 price target from HC Wainwright & Co., indicating a positive outlook from the analyst.
The reiteration of a Buy rating and maintenance of an $18 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in the company's future performance. This endorsement is likely to instill confidence among investors, potentially leading to a positive short-term impact on ROIV's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100